Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Jan;15(1):81–86. doi: 10.1128/aac.15.1.81

Activity of 2,4-Diaminoquinazoline Compounds against Candida species

Robert A Castaldo 1, Dieter W Gump 2, John J McCormack 3
PMCID: PMC352604  PMID: 426507

Abstract

Forty recent clinical isolates of three different Candida sp. were tested in the microtiter system for susceptibility to two new 2,4-diaminoquinazoline (DAQ) compounds, amphotericin B and flucytosine. The two DAQ preparations showed activity similar to amphotericin B and flucytosine. The geometric mean minimal inhibitory concentrations for these four drugs were as follows: DAQ 1A, 0.64 μg/ml; DAQ 2A, 1.39 μg/ml; amphotericin B, 1.03 μg/ml; and flucytosine, 0.72 μg/ml. An additional seven DAQ compounds were tested but showed less or no activity against 17 Candida isolates. Forty-eight-hour viability studies with DAQ 2A alone or in combination with amphotericin B, flucytosine, or sulfamethoxazole were carried out with one isolate of intermediate susceptibility to each of these agents except sulfamethoxazole. For this isolate the combination of DAQ 2A and sulfamethoxazole was synergistic, and the combination of DAQ 2A and AMB was either synergistic or additive, whereas the combination of DAQ 2A and flucytosine was antagonistic. Although regrowth of cultures exposed to DAQ 2A was noted over a 48-h period, neither degradation of the drug nor development of resistance to the drug could be detected. Swiss white mice receiving DAQ 1A at a dose of 6 mg/kg for 5 days showed no obvious signs of toxicity, including weight loss.

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anséhn S., Granström S., Höjer H., Nilsson L., Akesson E., Lundin A., Thore A. In-vitro effects of Candida albicans of amphotericin B combined with other antibiotics. Preliminary observations. Scand J Infect Dis Suppl. 1976;(9):62–66. [PubMed] [Google Scholar]
  2. Beggs W. H., Sarosi G. A., Andrews F. A. Synergistic action of amphotericin B and rifampin on Candida albicans. Am Rev Respir Dis. 1974 Nov;110(5):671–673. doi: 10.1164/arrd.1974.110.5.671. [DOI] [PubMed] [Google Scholar]
  3. Beggs W. H., Sarosi G. A., Steele N. M. Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B. Antimicrob Agents Chemother. 1976 Jun;9(6):863–865. doi: 10.1128/aac.9.6.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennet J. E. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. doi: 10.7326/0003-4819-86-3-319. [DOI] [PubMed] [Google Scholar]
  5. Bennett J. E. Chemotherapy of systemic mycoses (first of two parts). N Engl J Med. 1974 Jan 3;290(1):30–32. doi: 10.1056/NEJM197401032900107. [DOI] [PubMed] [Google Scholar]
  6. Bennett J. E. Chemotherapy of systemic mycoses (second of two parts). N Engl J Med. 1974 Feb 7;290(6):320–323. doi: 10.1056/NEJM197402072900607. [DOI] [PubMed] [Google Scholar]
  7. Bertino J. R., Sawicki W. L., Lindquist C. A., Gupta V. S. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 1977 Jan;37(1):327–328. [PubMed] [Google Scholar]
  8. Hariri A. R., Larsh H. W. In vitro and in vivo activity of 2,4-diamino-6-(2-(3,4-dichlorophenyl)acetamido) quinazoline against Cryptococcus neoformans. Proc Soc Exp Biol Med. 1976 Jan;151(1):173–176. doi: 10.3181/00379727-151-39168. [DOI] [PubMed] [Google Scholar]
  9. Hermans P. E. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc. 1977 Nov;52(11):687–693. [PubMed] [Google Scholar]
  10. Hoeprich P. D., Barry A. L., Fay G. D. Synthetic medium for susceptibility testing. Antimicrob Agents Chemother (Bethesda) 1970;10:494–497. [PubMed] [Google Scholar]
  11. Hynes J. B., Hough L. V., Smith A. B., Gale G. R. Activity of selected 2,4-diaminoquinazolines against Candida albicans in vitro. Proc Soc Exp Biol Med. 1976 Nov;153(2):230–232. doi: 10.3181/00379727-153-39516. [DOI] [PubMed] [Google Scholar]
  12. Lew M. A., Beckett K. M., Levin M. J. Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B. J Infect Dis. 1977 Aug;136(2):263–270. doi: 10.1093/infdis/136.2.263. [DOI] [PubMed] [Google Scholar]
  13. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shadomy S., Wagner G., Espinel-Ingroff E., Davis B. A. In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother. 1975 Aug;8(2):117–121. doi: 10.1128/aac.8.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES